NANOTECHNOLOGY-BASED THERAPIES IN THE TREATMENT OF TYPE 2 DIABETES: A NARRATIVE REVIEW

Jagoda Józefczyk; Paweł Buć; Karolina Buć; Łukasz Krzystek; Konrad Zieliński; Karolina Ganczar; Michał Mazurek; Marianna Rudzińska; Mikołaj Zalewski; Stanisław Jurkowski

doi:10.31435/ijitss.4(48).2025.4418

Authors

Jagoda Józefczyk Pomeranian Medical University, Szczecin, Poland https://orcid.org/0009-0007-5235-2074
Paweł Buć Pomeranian Medical University, Szczecin, Poland https://orcid.org/0009-0001-1533-6610
Karolina Buć Pomeranian Medical University, Szczecin, Poland https://orcid.org/0009-0000-8491-7200
Łukasz Krzystek Pomeranian Medical University, Szczecin, Poland https://orcid.org/0009-0001-1988-0402
Konrad Zieliński Pomeranian Medical University, Szczecin, Poland https://orcid.org/0009-0005-3652-592X
Karolina Ganczar University Teaching Hospital named after F. Chopin, Rzeszów, Poland https://orcid.org/0009-0003-8152-8076
Michał Mazurek University Teaching Hospital named after F. Chopin, Rzeszów, Poland https://orcid.org/0009-0005-7111-2397
Marianna Rudzińska Pomeranian Medical University, Szczecin, Poland https://orcid.org/0009-0002-9622-7439
Mikołaj Zalewski Pomeranian Medical University, Szczecin, Poland https://orcid.org/0009-0002-7803-6145
Stanisław Jurkowski Pomeranian Medical University, Szczecin, Poland https://orcid.org/0009-0005-9715-8385

DOI:

https://doi.org/10.31435/ijitss.4(48).2025.4418

Keywords:

Diabetes Mellitus Type 2, Nanotechnology, Nanoparticles, Drug Delivery Systems, Nanomedicine Diabetes, Nanoparticle-Based Therapy Diabetes

Abstract

Type 2 diabetes mellitus (T2DM) remains a major global health burden, driven by insulin resistance, progressive β-cell dysfunction, chronic inflammation, and metabolic dysregulation. Conventional pharmacotherapies often exhibit limited bioavailability, suboptimal targeting, and insufficient capacity to modulate the underlying mechanisms of disease progression. In recent years, nanotechnology has emerged as a highly promising therapeutic strategy capable of addressing these limitations. This narrative review evaluates current advancements in nanotechnology-based interventions for T2DM, with a focus on nanocarrier design, mechanisms of action, and translational potential.

Across the analyzed studies, diverse nanoplatforms—including polymeric nanoparticles, lipid-based nanocarriers, nanomicelles, PLGA systems, bilosomes, gold nanoparticles, and stimulus-responsive Pickering emulsions—demonstrated significant improvements in drug stability, controlled release, intestinal absorption, and metabolic outcomes. Notably, nanocarriers enhanced the therapeutic performance of incretin-based agents (GLP-1, liraglutide), enabled progress toward oral insulin delivery, and increased the bioavailability of conventional antidiabetic drugs such as metformin and glimepiride. Additionally, nanostructures encapsulating natural bioactive compounds (e.g., naringenin, oleanolic acid, resveratrol) exhibited potent antioxidant, anti-inflammatory, and metabolic benefits. Several innovative systems further demonstrated glucose- or pH-responsive behavior, enabling intelligent and targeted drug release.

Preclinical evidence consistently showed improved glycemic control, enhanced β-cell protection, reduced inflammatory markers, and favorable effects on lipid metabolism and body weight. However, the predominance of in vitro and in vivo animal studies underscores the need for robust clinical investigations to evaluate long-term safety, pharmacokinetics, and real-world therapeutic efficacy.

Overall, nanotechnology offers a promising avenue for the development of more effective, precise, and multidimensional treatments for T2DM. Continued translational and clinical research is essential to support its integration into future diabetes management.

References

Wang, X., Tian, R., Liang, C., Jia, Y., Zhao, L., Xie, Q., Huang, F., & Yuan, H. (2025). Biomimetic nanoplatform with microbiome modulation and antioxidant functions ameliorating insulin resistance and pancreatic β-cell dysfunction for T2DM management. Biomaterials, 313, 122804. https://doi.org/10.1016/j.biomaterials.2024.122804

Liu, Z., Chen, W., Zhang, J., Huang, T., Hong, Y., Zhao, T., Liu, M., Chen, Q., Yang, Y., Wang, S., Wang, J., Ying, X., Li, Y., Huang, Q., & Ai, K. (2025). UCP2 inhibition eliminates pancreatic β cell autoinflammation in T2DM with islet-mitochondrial sequential targeting nanomedicines. Nature communications, 16(1), 6840. https://doi.org/10.1038/s41467-025-61883-y

Yuan, M., Wang, Y., Wan, Y., Li, S., Tang, J., Liang, X., Zeng, B., Li, M., Wei, X., Li, X., Guo, L., & Guo, Y. (2024). Novel sodium tauroursodeoxycholate-based multifunctional liposomal delivery system for encapsulation of oleanolic acid and combination therapy of type 2 diabetes mellitus. International journal of pharmaceutics, 666, 124803. https://doi.org/10.1016/j.ijpharm.2024.124803

Low, C. Y., Gan, W. L., Lai, S. J., Tam, R. S., Tan, J. F., Dietl, S., Chuah, L. H., Voelcker, N., & Bakhtiar, A. (2025). Critical updates on oral insulin drug delivery systems for type 2 diabetes mellitus. Journal of nanobiotechnology, 23(1), 16. https://doi.org/10.1186/s12951-024-03062-7

Pandey, A., Rath, G., Chawala, R., & Goyal, A. K. (2025). A comprehensive review on liraglutide and novel nanocarrier-based systems for the effective delivery of liraglutide. Naunyn-Schmiedeberg's archives of pharmacology, 398(7), 8241–8258. https://doi.org/10.1007/s00210-025-03918-1

Subedi, L., Bamjan, A. D., Phuyal, S., Shim, J. H., Cho, S. S., Seo, J. B., Chang, K. Y., Byun, Y., Kweon, S., & Park, J. W. (2025). An oral liraglutide nanomicelle formulation conferring reduced insulin-resistance and long-term hypoglycemic and lipid metabolic benefits. Journal of controlled release : official journal of the Controlled Release Society, 378, 637–655. https://doi.org/10.1016/j.jconrel.2024.12.039

Qushawy, M., Alanazi, M. A., Hikal, W. M., Amirthalingam, P., Abu-Gharbieh, E., Almanzalawi, W. S., Mortagi, Y., Elsherbiny, N., & Elsherbini, A. M. (2025). Optimized Nanostructured Lipid Carriers for Metformin: Enhanced Anti-Inflammatory Activity and Protection Against Type 2 Diabetes-Induced Organ Damage. International journal of nanomedicine, 20, 3765–3788. https://doi.org/10.2147/IJN.S506631

Guo, S., & Li, H. (2025). Chitosan-Derived Nanocarrier Polymers for Drug Delivery and pH-Controlled Release in Type 2 Diabetes Treatment. Journal of fluorescence, 35(6), 3895–3904. https://doi.org/10.1007/s10895-024-03810-w

Loyola-Leyva, A., Hernandez-Vidales, K., Ruiz-Garcia, J., & Loyola-Rodriguez, J. P. (2025). Characterization of Green Synthesized Nanoparticles with Anti-diabetic Properties. A Systematic Review. Current diabetes reviews, 21(7), 67–85. https://doi.org/10.2174/0115733998306451240425135229

Khopade, S., Agnihotri, T. G., Baviskar, S., Pavar, B., Gomte, S. S., Maskar, T., Sharma, N., Kumar, H., Behera, S. K., & Jain, A. (2025). Sublingual Delivery of Human GLP-1 Loaded Nanoliposomal Hydrogel for Treatment of Type 2 Diabetes Mellitus. AAPS PharmSciTech, 26(5), 155. https://doi.org/10.1208/s12249-025-03152-1

Vidhate, M. K., Gomte, S. S., Singh, N., Suthar, D., & Jain, A. (2025). Exploring the hypoglycemic potential of HuGLP-1-loaded bilosomes in controlling type 2 diabetes mellitus. Therapeutic delivery, 16(10), 907–922. https://doi.org/10.1080/20415990.2025.2557183

Guo, Y., Xu, M., Chen, J., Che, J., Zhu, W., Zheng, Y., Huang, W., Dai, W., Chen, H., Zhai, L., Zhang, L., & Guan, Y. Q. (2025). Preparation and characterization of glutamine/chito-oligosaccharide modified zein nanoparticles: Controlled release naringin and anti-diabetes. Food chemistry, 493(Pt 1), 145615. https://doi.org/10.1016/j.foodchem.2025.145615

Soliman, A. Y., Elguindy, N. M., Saleh, A. M., & Balbaa, M. (2025). Biochemical and molecular evaluation of resveratrol and selenium nanoparticles in managing type 2 diabetes and its complications. Scientific reports, 15(1), 25565. https://doi.org/10.1038/s41598-025-11156-x

Sun, Q., Man, J., Zhang, Y., Ji, M., Song, X., Li, J., & Li, J. (2025). Poly (lactic-co-glycolic acid) (PLGA) nanoparticles for sustained release of metformin hydrochloride within cells: A therapy for Type 2 diabetes mellitus. Colloids and surfaces. B, Biointerfaces, 256(Pt 1), 114998. https://doi.org/10.1016/j.colsurfb.2025.114998

Forgham, H., Matre, S. V., Karen Chung, K. H., Tahir, M. S., Ali, S. A., Kikuchi, K., Kaur, A., Qiao, R., Kakinen, A., Qamar, A. Z., Davis, T. P., & Javed, I. (2025). Amyloid Targeting-Gold Nanoparticles-Assisted X-ray Therapy Rescues Islet β-Cells from Amyloid Fibrils and Restores Insulin Homeostasis. ACS nano, 19(5), 5460–5474. https://doi.org/10.1021/acsnano.4c13916

Karthick, V., Zahir, A. A., Amalraj, S., Rahuman, A. A., Anbarasan, K., & Santhoshkumar, T. (2025). Sustained release of nano-encapsulated glimepiride drug with chitosan nanoparticles: A novel approach to control type 2 diabetes in streptozotocin-induced Wistar albino rats. International journal of biological macromolecules, 287, 138496. https://doi.org/10.1016/j.ijbiomac.2024.138496

Chettupalli, A. K., Kar, N. R., Iswariya, V. T., Panigrahy, U. P., Singh, L. P., Roy, H., Urs, D., V, M., Mandadi, S. R., Haque, M. A., Rana, R., & Emran, T. B. (2025). Development and optimization of dapagliflozin oral nano-bilosomes using response surface method: in vitro evaluation, in vivo evaluation. Nanotheranostics, 9(1), 1–19. https://doi.org/10.7150/ntno.99271

Zhang, W., Wang, Y., Zhang, X., Zhang, Y., Yu, W., Tang, H., & Yuan, W. E. (2025). Polyzwitterion-branched polycholic acid nanocarriers based oral delivery insulin for long-term glucose and metabolic regulation in diabetes mellitus. Journal of nanobiotechnology, 23(1), 133. https://doi.org/10.1186/s12951-025-03190-8

Xu, M., Xia, M., Yang, L., Song, H., Li, J., Fan, H., & Liu, H. (2025). Preparation of size-controlled soy hull polysaccharide nanomicelles and evaluation of hypoglycaemic activity in type 2 diabetes zebrafish. International journal of biological macromolecules, 321(Pt 4), 146587. https://doi.org/10.1016/j.ijbiomac.2025.146587

Chen, Q., Ye, T., Yang, S., Fan, L., Shang, C., Feng, Y., Li, J., Wang, Y., Yu, G., & Dai, J. (2025). Multiple non-covalent bonds reinforced pH/glucose-responsive alginate-stabilized Pickering emulsion for diacylated anthocyanin intestinal delivery. International journal of biological macromolecules, 310(Pt 2), 142721. https://doi.org/10.1016/j.ijbiomac.2025.142721